Keywords: ThromboGenics, Ocriplasmin, VMA, 2011 financial results, BLA
ThromboGenics confident as it plans for ocriplasmin launch
Article | 12 March 2012
Belgian biopharma firm ThromboGenics (Euronext Brussels: THR) says that, over the past 12 months, it has built its capabilities in anticipation ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
